Literature DB >> 34242102

Faricimab: Two in the Bush Is Proving Better than One in the Hand?

Ashish Sharma1, Nilesh Kumar1, Nikulaa Parachuri1, Francesco Bandello2, Baruch D Kuppermann3, Anat Loewenstein4.   

Abstract

Entities:  

Year:  2021        PMID： 34242102     DOI： 10.1080/09273948.2021.1931350

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN： 0927-3948            Impact factor:   3.070


× No keyword cloud information.
  2 in total

1.  Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials.

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Dhatri Karanam; Baruch D Kuppermann; Francesco Bandello; Carl D Regillo
Journal:  Eye (Lond)       Date:  2021-10-30       Impact factor: 3.775

Review 2.  Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.

Authors:  Sławomir Liberski; Małgorzata Wichrowska; Jarosław Kocięcki
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.